ATI-9494 / Aclaris - LARVOL DELTA

Second Quarter 2026 Highlights, Recent Updates and Upcoming Catalysts (Investing News Network (INN)) - "Initiation of Phase 2b Clinical Program for Modzatinib (ATI-2138), a Potent and Selective Investigational Inhibitor of ITK and JAK3, Planned for the Fourth Quarter of 2026...On Track for Expected Fourth Quarter 2026 Filing of Investigational New Drug (IND) Application for ATI-9494, Aclaris' Investigational Dual Inhibitor of ITK and TXK."

IND • New P2b trial • Dermatitis • Immunology • Inflammation

Presented Data Characterizing Potency, Selectivity, and Target Occupancy of ATI-9494 (Investing News Network (INN)) - "New preclinical data presented at the 2026 Federation of American Societies for Experimental Biology (FASEB) Immuno receptors and Immunology Science Research Conference included results from cellular target engagement studies that demonstrated potent engagement of ITK by ATI-9494 and its ability to block functional activation of the TCR pathway. ATI-9494 demonstrated potency up to 25 times greater than soquelitinib (CPI-818) across multiple biochemical and functional cellular assays."

Preclinical • Immunology

Confirmed Intent to File Investigational New Drug (IND) Application for Lead ITK Inhibitor ATI-9494 in the Second Half of 2026 (GlobeNewswire)

IND • Immunology

Fourth Quarter 2025 Highlights and Recent Updates (The Manila Times) - "Confirmed Expectation of Top Line Results in the Second Half of 2026 from Ongoing Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug: This randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate bosakitug in approximately 96 patients with moderate-to-severe AD...Aclaris intends to file an IND for ATI-9494 in the second half of 2026."

IND • P2 data • Atopic Dermatitis • Immunology